Melbourne, Australia – February 19, 2026 – Q-Sera Pty Ltd, an Australian venture-backed company, today announced that leading Japanese medical device company, Terumo Corporation has launched VenoJect II RAPClotTM evacuated blood collection tubes in the Japanese market. These next-generation tubes incorporate Q-Sera’s patent protected technology and will improve laboratory management and patient outcomes.
Even in anticoagulated blood, RAPClot™ rapid serum tubes rapidly produce high quality serum in five minutes. In the case of the VenoJect II RAPClot tubes, formulated to clot up to 6U/ml heparin. This is the first real innovation in the Japanese blood collection tube market in decades, reducing the turnaround time from sample collection to serum analysis compared with current technologies and improving laboratory management. The ability of RAPClot tubes to generate high quality serum in five minutes and to clot anti-coagulated blood samples represents a substantial step forward in patient diagnosis.
Terumo Corporation has the exclusive rights to use Q-Sera’s technology to manufacture and market their VenoJect II RAPClot tubes in Japan. This has also involved the scaling-up of Q-Sera’s recombinant protein, ecarin (RAPClot) which can now be manufactured at commercial scale to a high quality level using standard biopharmaceutical processes.
Michael Grant, CEO of Q-Sera, said, “Q-Sera is pleased to announce the first launch of its patented technology by Terumo Corporation in the Japanese market. Japan has a history of innovation in blood collection tubes with Terumo Corporation a leader in this sector and together we look forward to launching this next-generation tube technology to benefit patients and the health care system”.
Wataru Ninokura, Director of Essential Medical Products, Terumo said, VenoJect II “RAPClot™ tubes are a true innovation in blood collection tubes and have the potential to dramatically improve issues such as coagulation time, heparinized blood, and fibrin strands in tests with serum. It will be a great pleasure for us to be able to directly contribute to improving the accuracy of diagnosis.”.
Michael Grant, CEO also said ‘Q-Sera owns the cell line license, with its recombinant ecarin manufactured by Bora Biologics. Q-Sera is actively pursuing partners for blood collection tube markets and diagnostic sectors outside Japan’. If you are interested, please contact Q-Sera as below.
About us:
About Q-Sera
Q-Sera is a start-up company that is commercialising intellectual property developed at The University of Queensland (UQ) and licensed to Q-Sera by UniQuest, UQ’s commercialisation company. Q-Sera’s licensed intellectual property includes active proteins and formulations for a novel serum collection tube. The technology behind Q-Sera involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to produce high quality serum for biochemical analysis. The company’s lead active protein RAPClot™ is manufactured recombinantly at commercial scale and is supported by investment from two of Australia’s premier life science investors, the Medical Research Commercialisation Fund (MRCF), managed by Australia’s largest venture capital firm Brandon Capital Partners, and Uniseed, Australia’s longest running venture fund operating at selected Australian Universities as well as the national science agency CSIRO with additional investment from the UniQuest Extension Fund. The company also acknowledges the support of the Australian Government, through Austrade.
For more information visit: www.q-sera.com or directly at [email protected].
About Terumo
Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of “Contributing to Society through Healthcare.” Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions.
For more information visit: https://www.terumo.com/.
For more information.
Q-Sera - Call: +61 477358623, E-mail: [email protected]
Contact details:
Media Contacts - Australia
Brandon Capital: Ruth Heenan - [email protected] 0416 565 332
